HPV-Associated Head and Neck Cancer Drug in the Works – Monthly Prescribing Reference

HPV-Associated Head and Neck Cancer Drug in the Works
Monthly Prescribing Reference
Advaxis submitted an Application for Orphan Drug Designation to the FDA for ADXS-HPV, a drug candidate for the treatment of human papillomavirus (HPV)-associated head and neck cancer. ADXS-HPV is currently being evaluated in a Phase 1/2 study in 

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *